Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s hypertension forecast will answer the following questions:

  • Of all people with hypertension, how many in each country under study have been formally diagnosed?
  • Of all people diagnosed with hypertension, how many in each country under study are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hypertension over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 27 hypertension patient populations, including the following:

  • Total prevalent cases of hypertension.
  • Total prevalent cases of prehypertension.
  • Diagnosed prevalent cases of hypertension.
  • Diagnosed drug-treated prevalent cases of hypertension.
  • Diagnosed drug-treated prevalent cases of controlled hypertension.
  • Total prevalent cases of hypertension controlled with one antihypertensive drug.
  • Total prevalent cases of hypertension controlled with two antihypertensive drugs.
  • Total prevalent cases of hypertension controlled with three or more antihypertensive drugs.
  • … and many more (details available on request).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Atrial Fibrillation – Landscape & Forecast – Disease Landscape & Forecast (G7)
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF can lead to blood clots, increasing the risk of stroke…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
Report
Heart Failure – Landscape & Forecast – Disease Landscape & Forecast (G7)
Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…
Report
Inflammatory Myositis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of inflammatory myositis (IM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…